United-Guardian Q3 sales rise 54% as Renacidin gains formulary coverage
The US maker of pharmaceuticals, cosmetic ingredients and medical lubricants reported Q3 2026 net income of $930,912, with Renacidin the main driver of pharmaceutical growth.
United-Guardian Inc announced its third-quarter 2026 results on 9 November. Net sales were about $3.49m, up 54% on the same quarter a year earlier. Net income was $930,912, or $0.20 per share, an increase of 247%.
For the first nine months of 2026, net sales rose 25% to $9.48m.
The company said pharmaceutical sales grew 29%, driven mainly by Renacidin. It attributed part of that growth to expanded formulary coverage secured earlier in 2026. The summary available does not say which formularies or payers were involved.
Outside pharmaceuticals, cosmetic ingredient sales rose 187% and medical lubricant sales increased 20%.
Why it matters
- Market-access teams can note that United-Guardian credits formulary coverage won earlier in 2026 as a contributor to Renacidin sales growth.
- The available details do not identify the specific formularies or the size of the coverage effect, so the link should not be over-read.
- The product mix is broad, covering pharmaceuticals, cosmetic ingredients and medical lubricants, so group figures reflect more than one regulatory pathway.
Company's press release (SEC filing): United Guardian Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
